Collplant announces publication highlighting its rhcollagen-based photocurable dermal filler in the plastic and reconstructive surgery journal

Preclinical modeling demonstrates potential for filler to enhance cell proliferation and new tissue regeneration for aesthetic medicine applications rehovot, israel, dec. 2, 2021 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the publication of an article in the plastic and reconstructive surgery journal titled "the potential use of novel plant-derived recombinant human collagen in aesthetic medicine."  the article highlights favorable in-vitro and in-vivo results of collplant's photocurable dermal filler as well as other potential applications of this collagen technology in aesthetic medicine.
CLGN Ratings Summary
CLGN Quant Ranking